Matching articles for "ProAir RespiClick"

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • September 7, 2020;  (Issue 1606)
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several...
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several guidelines and review articles on COPD treatment have been published in recent years. Treatment of acute exacerbations is not discussed here.
Med Lett Drugs Ther. 2020 Sep 7;62(1606):137-44 | Show Full IntroductionHide Full Introduction

Comparison Table: Inhaled Short-Acting Bronchodilators for Treatment of COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • September 7, 2020;  (Issue 1606)
...
View the Comparison Table: Inhaled Short-Acting Bronchodilators for Treatment of COPD
Med Lett Drugs Ther. 2020 Sep 7;62(1606):e144-5 | Show Full IntroductionHide Full Introduction

Table: Correct Use of Inhalers for COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • September 7, 2020;  (Issue 1606)
...
View the Table: Correct Use of Inhalers for COPD
Med Lett Drugs Ther. 2020 Sep 7;62(1606):e150-4 | Show Full IntroductionHide Full Introduction

Drugs for Asthma

   
The Medical Letter on Drugs and Therapeutics • August 28, 2017;  (Issue 1528)
The goal of asthma treatment is to control symptoms and prevent exacerbations. Management of acute exacerbations of asthma is not discussed...
The goal of asthma treatment is to control symptoms and prevent exacerbations. Management of acute exacerbations of asthma is not discussed here.
Med Lett Drugs Ther. 2017 Aug 28;59(1528):139-46 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Inhaled Drugs for Treatment of Asthma (online only)

   
The Medical Letter on Drugs and Therapeutics • August 28, 2017;  (Issue 1528)
...
View the Comparison Table: Some Inhaled Drugs for Treatment of Asthma
Med Lett Drugs Ther. 2017 Aug 28;59(1528):e146-9 | Show Full IntroductionHide Full Introduction

Comparison Table: Correct Use of Inhalers for Asthma (online only)

   
The Medical Letter on Drugs and Therapeutics • August 28, 2017;  (Issue 1528)
...
View the Comparison Table: Correct Use of Inhalers
Med Lett Drugs Ther. 2017 Aug 28;59(1528):e150-2 | Show Full IntroductionHide Full Introduction

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • April 10, 2017;  (Issue 1518)
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Updated...
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Updated guidelines for treatment of COPD have been published in recent years.
Med Lett Drugs Ther. 2017 Apr 10;59(1518):57-62 | Show Full IntroductionHide Full Introduction

Comparison Table: Inhaled Short-Acting Bronchodilators for COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • April 10, 2017;  (Issue 1518)
...
View the Comparison Table: Inhaled Short-Acting Bronchodilators for COPD
Med Lett Drugs Ther. 2017 Apr 10;59(1518):e62-3 | Show Full IntroductionHide Full Introduction

In Brief: A New Albuterol Inhaler (ProAir RespiClick) for Asthma

   
The Medical Letter on Drugs and Therapeutics • October 26, 2015;  (Issue 1480)
The short-acting beta2-agonist albuterol sulfate is now available as a dry powder for inhalation (ProAir RespiClick – Teva) for prevention and treatment of broncho spasm in patients ≥12 years old. ProAir...
The short-acting beta2-agonist albuterol sulfate is now available as a dry powder for inhalation (ProAir RespiClick – Teva) for prevention and treatment of broncho spasm in patients ≥12 years old. ProAir RespiClick is the only short-acting beta2-agonist dry powder inhaler available in the US.



Metered-dose inhalers (MDIs) use a hydrofluoroalkane (HFA) propellant. They require coordination of inhalation with actuation; using them with a valved holding chamber minimizes this need, but decreases portability because of the size of the chamber. Dry powder inhalers such as ProAir RespiClick, which are breath-actuated, do not require a propellant and do not have to be primed before use. They do not require coordination of inhalation with actuation, but patients must be capable of performing a rapid, deep inhalation, which might be difficult during a severe asthma attack.

The recommended dose of ProAir RespiClick for treatment of bronchospasm is 2 inhalations, but 1 inhalation may be sufficient for some patients. The dose can be repeated every 4-6 hours as needed. For prevention of exercise-induced bronchospasm, the recommended dosage is 2 inhalations 15-30 minutes before exercise.

Each ProAir RespiClick inhaler includes a dose counter. Opening the mouthpiece cap readies a dose for administration and causes the counter to count down by 1; closing the cap without inhaling the medication wastes that dose. The inhaler should be cleaned with a dry cloth as needed.

ProAir RespiClick may contain trace levels of milk proteins; it is contraindicated for use in patients with a history of a severe hypersensitivity reaction to milk proteins.

Download complete U.S. English article

Med Lett Drugs Ther. 2015 Oct 26;57(1480):150 | Show Full IntroductionHide Full Introduction